Information  X 
Enter a valid email address

AllergyTherapeuticsPLC Ord0.1P (AGY)

Date Time Source Announcement
08 Aug 2018 7:00 am
RNS
Notice of Results
27 Jul 2018 5:26 pm
RNS
Holding(s) in Company
26 Jul 2018 12:02 pm
RNS
Holding(s) in Company
19 Jul 2018 10:19 am
RNS
Results of Placing and Subscription
  7:00 am
RNS
Proposed placing & subscription to raise �10.6m
16 Jul 2018 8:53 am
RNS
BLOCK LISTING SIX MONTHLY RETURN
13 Jul 2018 9:40 am
EQS
Allergy Therapeutics (AGY): Steady performance ...
12 Jul 2018 7:00 am
RNS
Trading Update
25 Jun 2018 7:52 am
RNS
Positive data of Pollinex Quattro Grass vaccine
29 May 2018 7:00 am
RNS
Positive data with house-dust mite immunotherapy
21 May 2018 12:25 pm
EQS
Allergy Therapeutics (AGY): Opening the door to...
  7:00 am
RNS
Positive top-line results from Grass Ph II study
14 May 2018 7:00 am
RNS
Publication of MCT Adjuvant Data
16 Mar 2018 3:38 pm
RNS
Grant of Awards under Long Term Incentive Plan
  12:53 pm
RNS
Director/PDMR Shareholding
07 Mar 2018 9:30 am
RNS
Hardman: Clinical development towards submission
  7:00 am
RNS
Interim Results
28 Feb 2018 7:00 am
RNS
Polyvac? Peanut CMO appointed
12 Feb 2018 7:00 am
RNS
Completion of recruitment in PQ Grass Ph II trial
02 Feb 2018 7:15 am
RNS
Hardman Research: Growth in a tough market
31 Jan 2018 7:00 am
RNS
Trading Update
10 Jan 2018 3:19 pm
RNS
Holdings in Company
09 Jan 2018 7:00 am
RNS
PQ Birch Phase III trial completes recruitment
12 Dec 2017 7:00 am
RNS
Co-development agreement with Ergomed plc
07 Dec 2017 5:08 pm
RNS
Holding(s) in Company
22 Nov 2017 11:36 am
RNS
Result of AGM
21 Nov 2017 7:00 am
RNS
Block Listing Application
13 Nov 2017 7:00 am
RNS
Allergy Therapeutics to Present at Jefferies 2017
07 Nov 2017 12:59 pm
RNS
Director/PDMR Shareholding
19 Oct 2017 4:14 pm
RNS
Publication of Annual Report and notice of AGM
  7:00 am
RNS
Commencement of dosing in PQ Grass Phase II Trial
12 Oct 2017 5:39 pm
RNS
Holding(s) in Company
  2:55 pm
RNS
Director/PDMR Shareholding
10 Oct 2017 7:15 am
RNS
Hardman Research: Continuing to gain market share
28 Sep 2017 7:00 am
RNS
Preliminary Results
18 Sep 2017 7:00 am
RNS
Approval for PQ Grass Phase II trial
11 Sep 2017 7:00 am
RNS
Expansion of Clinical Development and R&D teams
15 Aug 2017 7:00 am
RNS
Notice of Results
18 Jul 2017 7:00 am
RNS
Trading Update
06 Jul 2017 7:00 am
RNS
Publication of adjuvant studies in journals
27 Jun 2017 7:00 am
RNS
Investor and analyst site visits
19 Jun 2017 7:00 am
RNS
Satellite Symposium at EAACI 2017
06 Jun 2017 7:00 am
RNS
Directorate changes
02 Jun 2017 12:55 pm
RNS
Holding(s) in Company
13 Apr 2017 7:00 am
RNS
Issue of Equity
05 Apr 2017 7:15 am
RNS
Hardman Research: Development across portfolio
29 Mar 2017 7:00 am
RNS
Interim Results for six months ended 31 Dec 2016
16 Mar 2017 7:00 am
RNS
First Patient in Pivotal Phase III Birch Study
09 Mar 2017 7:00 am
RNS
Notice of Interim Results
14 Feb 2017 7:00 am
RNS
House Dust Mite Allergy Vaccine Gains CTA Approval
08 Feb 2017 7:00 am
RNS
Directorate Change
01 Feb 2017 7:00 am
RNS
Positive Efficacy & Safety Data in Peanut Vaccine
20 Jan 2017 7:15 am
RNS
Hardman Research: Investment driving market share
19 Jan 2017 7:00 am
RNS
Trading Update
30 Dec 2016 2:31 pm
RNS
Grant of Awards
24 Nov 2016 5:23 pm
RNS
Result of AGM
02 Nov 2016 7:00 am
RNS
EU Patent Office grants patent for MCT
27 Oct 2016 1:10 pm
RNS
Issue of equity in respect of exercise of options
24 Oct 2016 1:35 pm
RNS
Annual Report and Accounts
10 Oct 2016 7:00 am
RNS
New data from novel adjuvant system
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t